Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.37 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.33 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6921388 | 0.94 | IKBKB (0.39) | HRH3ADORA1GPR119SCD5 | |
| SCHEMBL6822339 | 0.93 | CACNB4 (0.38) | HRH3ADORA1GPR119SCD5SLC16A3 | |
| Hydrochloric Acid SCHEMBL6822212 | 0.90 | HRH3 (0.40) | HRH3ADORA1 | |
| SCHEMBL6822059 | 0.87 | HRH3 (0.37) | HRH3ADORA1SLC16A3SLC16A1 | |
| Hydrochloric Acid SCHEMBL6821473 | 0.87 | HRH3 (0.42) | HRH3ADORA1 | |
| SCHEMBL6818748 | 0.85 | ADORA1 (0.40) | ADORA1 | |
| SCHEMBL6822257 | 0.82 | ADORA1 (0.43) | ADORA1 | |
| SCHEMBL6822588 | 0.82 | ADORA1 (0.41) | ADORA1 | |
| SCHEMBL6821959 | 0.81 | ADORA1 (0.42) | ADORA1 | |
| SCHEMBL6822033 | 0.81 | ADORA1 (0.41) | ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1313733-A1 | PYRAZOLOPYRIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002018382-A1 | PYRAZOLOPYRIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | ADRB1, ADRA1D, ADRB3 | HRH3 275/4885ADORA1 22/4885GPR119 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.